Copyright Reports & Markets. All rights reserved.

Global Novel Oral AntiCoagulants (NOAC) Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Novel Oral AntiCoagulants (NOAC)

      • 1.1 Definition of Novel Oral AntiCoagulants (NOAC)
      • 1.2 Novel Oral AntiCoagulants (NOAC) Segment by Type
        • 1.2.1 Global Novel Oral AntiCoagulants (NOAC) Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Direct Thrombin Inhibitors
        • 1.2.3 Direct Factor Xa Inhibitors
      • 1.3 Novel Oral AntiCoagulants (NOAC) Segment by Applications
        • 1.3.1 Global Novel Oral AntiCoagulants (NOAC) Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Deep Vein Thrombosis (DVT)
        • 1.3.3 Pulmonary Embolism
        • 1.3.4 Acute Coronary Syndrome
        • 1.3.5 Hemodialysis
        • 1.3.6 Others
      • 1.4 Global Novel Oral AntiCoagulants (NOAC) Overall Market
        • 1.4.1 Global Novel Oral AntiCoagulants (NOAC) Revenue (2014-2025)
        • 1.4.2 Global Novel Oral AntiCoagulants (NOAC) Production (2014-2025)
        • 1.4.3 North America Novel Oral AntiCoagulants (NOAC) Status and Prospect (2014-2025)
        • 1.4.4 Europe Novel Oral AntiCoagulants (NOAC) Status and Prospect (2014-2025)
        • 1.4.5 China Novel Oral AntiCoagulants (NOAC) Status and Prospect (2014-2025)
        • 1.4.6 Japan Novel Oral AntiCoagulants (NOAC) Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Novel Oral AntiCoagulants (NOAC) Status and Prospect (2014-2025)
        • 1.4.8 India Novel Oral AntiCoagulants (NOAC) Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Novel Oral AntiCoagulants (NOAC)
      • 2.3 Manufacturing Process Analysis of Novel Oral AntiCoagulants (NOAC)
      • 2.4 Industry Chain Structure of Novel Oral AntiCoagulants (NOAC)

      3 Development and Manufacturing Plants Analysis of Novel Oral AntiCoagulants (NOAC)

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Novel Oral AntiCoagulants (NOAC) Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Novel Oral AntiCoagulants (NOAC)
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Novel Oral AntiCoagulants (NOAC) Production and Capacity Analysis
      • 4.2 Novel Oral AntiCoagulants (NOAC) Revenue Analysis
      • 4.3 Novel Oral AntiCoagulants (NOAC) Price Analysis
      • 4.4 Market Concentration Degree

      5 Novel Oral AntiCoagulants (NOAC) Regional Market Analysis

      • 5.1 Novel Oral AntiCoagulants (NOAC) Production by Regions
        • 5.1.1 Global Novel Oral AntiCoagulants (NOAC) Production by Regions
        • 5.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Regions
      • 5.2 Novel Oral AntiCoagulants (NOAC) Consumption by Regions
      • 5.3 North America Novel Oral AntiCoagulants (NOAC) Market Analysis
        • 5.3.1 North America Novel Oral AntiCoagulants (NOAC) Production
        • 5.3.2 North America Novel Oral AntiCoagulants (NOAC) Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Novel Oral AntiCoagulants (NOAC) Import and Export
      • 5.4 Europe Novel Oral AntiCoagulants (NOAC) Market Analysis
        • 5.4.1 Europe Novel Oral AntiCoagulants (NOAC) Production
        • 5.4.2 Europe Novel Oral AntiCoagulants (NOAC) Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Novel Oral AntiCoagulants (NOAC) Import and Export
      • 5.5 China Novel Oral AntiCoagulants (NOAC) Market Analysis
        • 5.5.1 China Novel Oral AntiCoagulants (NOAC) Production
        • 5.5.2 China Novel Oral AntiCoagulants (NOAC) Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Novel Oral AntiCoagulants (NOAC) Import and Export
      • 5.6 Japan Novel Oral AntiCoagulants (NOAC) Market Analysis
        • 5.6.1 Japan Novel Oral AntiCoagulants (NOAC) Production
        • 5.6.2 Japan Novel Oral AntiCoagulants (NOAC) Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Novel Oral AntiCoagulants (NOAC) Import and Export
      • 5.7 Southeast Asia Novel Oral AntiCoagulants (NOAC) Market Analysis
        • 5.7.1 Southeast Asia Novel Oral AntiCoagulants (NOAC) Production
        • 5.7.2 Southeast Asia Novel Oral AntiCoagulants (NOAC) Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Novel Oral AntiCoagulants (NOAC) Import and Export
      • 5.8 India Novel Oral AntiCoagulants (NOAC) Market Analysis
        • 5.8.1 India Novel Oral AntiCoagulants (NOAC) Production
        • 5.8.2 India Novel Oral AntiCoagulants (NOAC) Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Novel Oral AntiCoagulants (NOAC) Import and Export

      6 Novel Oral AntiCoagulants (NOAC) Segment Market Analysis (by Type)

      • 6.1 Global Novel Oral AntiCoagulants (NOAC) Production by Type
      • 6.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type
      • 6.3 Novel Oral AntiCoagulants (NOAC) Price by Type

      7 Novel Oral AntiCoagulants (NOAC) Segment Market Analysis (by Application)

      • 7.1 Global Novel Oral AntiCoagulants (NOAC) Consumption by Application
      • 7.2 Global Novel Oral AntiCoagulants (NOAC) Consumption Market Share by Application (2014-2019)

      8 Novel Oral AntiCoagulants (NOAC) Major Manufacturers Analysis

      • 8.1 Johnson & Johnson
        • 8.1.1 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.1.2 Johnson & Johnson Product Introduction, Application and Specification
        • 8.1.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Bristol-Myers Squibb
        • 8.2.1 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.2.2 Bristol-Myers Squibb Product Introduction, Application and Specification
        • 8.2.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Boehringer Ingelheim
        • 8.3.1 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.3.2 Boehringer Ingelheim Product Introduction, Application and Specification
        • 8.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Sanofi
        • 8.4.1 Sanofi Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.4.2 Sanofi Product Introduction, Application and Specification
        • 8.4.3 Sanofi Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Daiichi Sankyo
        • 8.5.1 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.5.2 Daiichi Sankyo Product Introduction, Application and Specification
        • 8.5.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Armatheon
        • 8.6.1 Armatheon Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.6.2 Armatheon Product Introduction, Application and Specification
        • 8.6.3 Armatheon Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Aspen
        • 8.7.1 Aspen Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.7.2 Aspen Product Introduction, Application and Specification
        • 8.7.3 Aspen Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 AstraZeneca
        • 8.8.1 AstraZeneca Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.8.2 AstraZeneca Product Introduction, Application and Specification
        • 8.8.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Bayer
        • 8.9.1 Bayer Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.9.2 Bayer Product Introduction, Application and Specification
        • 8.9.3 Bayer Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Cellceutix
        • 8.10.1 Cellceutix Novel Oral AntiCoagulants (NOAC) Production Sites and Area Served
        • 8.10.2 Cellceutix Product Introduction, Application and Specification
        • 8.10.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Cosmo Pharmaceuticals
      • 8.12 CSL Behring
      • 8.13 Eisai
      • 8.14 GSK
      • 8.15 Marathon Pharmaceuticals
      • 8.16 Ockham Biotech
      • 8.17 Perosphere

      9 Development Trend of Analysis of Novel Oral AntiCoagulants (NOAC) Market

      • 9.1 Global Novel Oral AntiCoagulants (NOAC) Market Trend Analysis
        • 9.1.1 Global Novel Oral AntiCoagulants (NOAC) Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Novel Oral AntiCoagulants (NOAC) Regional Market Trend
        • 9.2.1 North America Novel Oral AntiCoagulants (NOAC) Forecast 2019-2025
        • 9.2.2 Europe Novel Oral AntiCoagulants (NOAC) Forecast 2019-2025
        • 9.2.3 China Novel Oral AntiCoagulants (NOAC) Forecast 2019-2025
        • 9.2.4 Japan Novel Oral AntiCoagulants (NOAC) Forecast 2019-2025
        • 9.2.5 Southeast Asia Novel Oral AntiCoagulants (NOAC) Forecast 2019-2025
        • 9.2.6 India Novel Oral AntiCoagulants (NOAC) Forecast 2019-2025
      • 9.3 Novel Oral AntiCoagulants (NOAC) Market Trend (Product Type)
      • 9.4 Novel Oral AntiCoagulants (NOAC) Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Novel Oral AntiCoagulants (NOAC) Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Novel Oral AntiCoagulants (NOAC) market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Novel Oral AntiCoagulants (NOAC) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Novel Oral AntiCoagulants (NOAC) market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Novel Oral AntiCoagulants (NOAC) in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Novel Oral AntiCoagulants (NOAC) manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Johnson & Johnson
        Bristol-Myers Squibb
        Boehringer Ingelheim
        Sanofi
        Daiichi Sankyo
        Armatheon
        Aspen
        AstraZeneca
        Bayer
        Cellceutix
        Cosmo Pharmaceuticals
        CSL Behring
        Eisai
        GSK
        Marathon Pharmaceuticals
        Ockham Biotech
        Perosphere

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Direct Thrombin Inhibitors
        Direct Factor Xa Inhibitors

        Segment by Application
        Deep Vein Thrombosis (DVT)
        Pulmonary Embolism
        Acute Coronary Syndrome
        Hemodialysis
        Others

        Buy now